nigel_clark

Kymab makes two senior appointments

pharmafile | June 5, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing arkinstall, clark, kymab 

Cambridge-based biopharma firm Kymab has hired Steve 
Arkinstall as a chief scientific officer, and Nigel Clark as VP 
and head of business development.

Clark (pictured) has 20 years’ experience in the biopharma industry at 
both public and private companies. He was previously a chief business
 officer at Syntaxin, and prior to that was head of business development 
at Vernalis for seven years.
 

Arkinstall takes overs 25 years’ experience to the firm spanning 
biopharmaceutical R&D, and having worked across several
 disease and specialist areas. 

Advertisement

He joins Kymab from
 Merck Serono, where over his 16-year career he has held a number of senior
 management roles including leadership of the Serono Research Institute in
 Boston, as well as head of global technologies and external innovation.
 

Christian Groendahl, chief executive of Kymab, says: “We are delighted to announce the appointments
 of Steve and Nigel to Kymab’s senior management team. We look forward to benefiting from both Steve and Nigel’s experience as we build Kymab into a global biotechnology company.”

Related Content

Sanofi to acquire Kymab for $1.1bn

Sanofi is to acquire clinical-stage biopharmaceutical company Kymab for approximately $1.1 billion. In addition to …

kymab

Chinese investors push Kymab backing to $100 million

Kymab, the UK-based antibody biopharmaceutical group, announced that it has secured $100 million in funding. …

hiv-infected_h9_t-cell_-_credit_national_institutes_of_health-web

Kymab demonstrates promising research for HIV vaccine development

Cambridge-based antibodies-to-medicines company Kymab has announced publication of research testing the first step in the …

The Gateway to Local Adoption Series

Latest content